/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.
/PRNewswire/ Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces that it.
Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Hansa Biopharma AB "Hansa" or the "Company", (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today.
/PRNewswire/ Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General.